Le, Tham TPrice, DavidErhard, ClementCook, BillQuinton, AnnaKatial, RohitChristoff, George CPerez-De-Llano, LuisAltraja, AlanBergeron , CelineBourdin, ArnaudKoh, Mariko SiyueLehtimäki, LauriMahboub, BassamPapadopoulos, Nikolaos GPfeffer, Paul ERhee, Chin KookCarter, VictoriaMartin, NeilTran, Trung NEVEREST Study Working Group2024-10-252024-10-252024-10-25Le, T T, Price, D, Erhard, C, Cook, B, Quinton, A, Katial, R, Christoff, G C, Perez-De-Llano, L, Altraja, A, Bergeron , C, Bourdin, A, Koh, M S, Lehtimäki, L, Mahboub, B, Papadopoulos, N G, Pfeffer, P E, Rhee, C K, Carter, V, Martin, N, Tran, T N & EVEREST Study Working Group 2024, 'Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022 : An Analysis of the International Severe Asthma Registry', Journal of Asthma and Allergy, vol. 2024, no. 17, pp. 1055-1069. https://doi.org/10.2147/JAA.S4680681178-6965https://hdl.handle.net/2164/24474Acknowledgments The authors thank all the ISAR collaborators (Appendix 1) and study participants, and Ekaterina Maslova of AstraZeneca for her contributions to the study design. Medical writing support was provided by Priyanka Narang, PhD, and Richard Claes, PhD, of PharmaGenesis London, London, UK, with funding from AstraZeneca.15965664engbiologicdisease burdenhealthcare resource utilizationsevere asthmaR MedicineSupplementary InformationRJournal article10.2147/JAA.S46806817